芯能科技(603105.SH):杭州鼎暉新趨勢擬減持公司不超2%股份
格隆匯11月28日丨芯能科技(603105.SH)公吿,因自身經營需求,杭州鼎暉新趨勢股權投資合夥企業(有限合夥)計劃採取集中競價交易方式減持公司股份,自減持計劃公吿披露日起15個交易日後的6個月內,減持不超過公司股份總數的2.00%,減持價格按市場價格確定。若在減持計劃實施期間公司發生派發紅利、轉增股本等股本除權、除息事項的,將根據股本變動對減持數量進行相應調整。
截至公吿披露日,作為浙江芯能光伏科技股份有限公司(以下簡稱“公司”)持股5%以上的機構股東,杭州鼎暉新趨勢股權投資合夥企業(有限合夥)持有公司無限售條件流通股43,526,000股,佔公司股本的8.7052%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.